Selective serotonin reuptake inhibitor use and risk of gestational hypertension.

The American Journal of Psychiatry
Sengwee TohSonia Hernández-Díaz

Abstract

The purpose of this study was to assess the effects of treatment with selective serotonin reuptake inhibitors (SSRIs) on the risks of gestational hypertension and preeclampsia. The authors analyzed data from 5,731 women with nonmalformed infants and no underlying hypertension who participated in the Slone Epidemiology Center Birth Defects Study from 1998 to 2007. Gestational hypertension was defined as incident hypertension diagnosed after 20 weeks of pregnancy, with and without proteinuria (i.e., with and without preeclampsia). The risks of gestational hypertension and preeclampsia were compared between women who did and did not receive SSRI treatment during pregnancy. Relative risks and 95% confidence intervals (CIs) were estimated using the Cox proportional hazards model, adjusting for prepregnancy sociodemographic, lifestyle, reproductive, and medical factors. Gestational hypertension was present in 9.0% of the 5,532 women who were not treated with SSRIs and 19.1% of the 199 women who were treated with SSRIs. Among women who received treatment, gestational hypertension was present in 13.1% of the 107 women who received treatment only during the first trimester and in 26.1% of the 92 women who continued treatment beyond the ...Continue Reading

Citations

Aug 28, 2009·Seminars in Reproductive Medicine·James M SwansonPathik D Wadhwa
Oct 21, 2010·Breastfeeding Medicine : the Official Journal of the Academy of Breastfeeding Medicine·Riccardo DavanzoAlessandro Amaddeo
Mar 24, 2012·American Journal of Epidemiology·Kristin PalmstenSonia Hernández-Díaz
Feb 15, 2013·Human Reproduction·Adam C Urato, Alice D Domar
Sep 8, 2011·Current Opinion in Obstetrics & Gynecology·Megan GalballyAndrew J Lewis
Nov 17, 2009·Journal of Clinical Psychopharmacology·Sengwee TohSonia Hernández-Díaz
Mar 5, 2016·International Journal of Preventive Medicine·Seyed Kazem Razavi RatkiAtefeh Shirinzade
Jul 21, 2012·Cardiology Clinics·Amanda R Vest, Leslie S Cho
Nov 8, 2011·General Hospital Psychiatry·Wayne J KatonAmelia R Gavin
Mar 23, 2012·British Journal of Clinical Pharmacology·Mary A De Vera, Anick Bérard
Sep 22, 2012·British Journal of Clinical Pharmacology·Luke E GrzeskowiakJanna L Morrison
Nov 3, 2012·British Journal of Clinical Pharmacology·Anick Bérard, Mary A De Vera
Oct 30, 2014·BJOG : an International Journal of Obstetrics and Gynaecology·R A CharltonL T W de Jong-van den Berg
May 16, 2015·Best Practice & Research. Clinical Obstetrics & Gynaecology·Teri Pearlstein
Feb 22, 2011·Best Practice & Research. Clinical Obstetrics & Gynaecology·Adam C Urato, Errol R Norwitz
Mar 18, 2015·CNS Spectrums·Lyndsay Ammon AvalosDe-Kun Li
Jan 15, 2015·Journal of Women's Health·Madhavi K ThombreClaudia Holzman
Jul 6, 2016·Frontiers in Cellular Neuroscience·Helena KaiholaInger Sundström-Poromaa
Nov 3, 2016·Pharmacoepidemiology and Drug Safety·Yanyan MaoYuelian Sun
Oct 21, 2011·American Journal of Hypertension·Ingrid M M van HaelstToine C G Egberts
Aug 24, 2013·The Australian and New Zealand Journal of Psychiatry·Philip Boyce
Dec 9, 2015·The Australian and New Zealand Journal of Psychiatry·Gin S MalhiAjeet B Singh
Jun 18, 2017·Expert Opinion on Drug Safety·Lars Henning Pedersen
Nov 28, 2013·Pharmaceuticals·Bengt KällénMargareta Reis
Jan 23, 2019·Current Drug Safety·Sabrina Youash, Verinder Sharma
Jul 23, 2013·Epidemiology·Kristin PalmstenSonia Hernández-Díaz
Mar 25, 2020·Paediatric and Perinatal Epidemiology·Kristin PalmstenGretchen Bandoli
Aug 23, 2020·International Journal of Molecular Sciences·Sabrina I HanswijkJudith R Homberg
Apr 9, 2010·Acta Clinica Belgica·Y Jacquemyn, O Zemtsova
May 31, 2018·BMC Pregnancy and Childbirth·Neily ZakiyahCatharina C M Schuiling-Veninga
Jul 17, 2019·The Journal of Pharmacology and Experimental Therapeutics·Weibin ZhaJoanne Wang
Sep 28, 2015·The International Journal of Risk & Safety in Medicine·Adam C Urato
Jul 29, 2017·British Journal of Cancer·M Boia-FerreiraA Senff-Ribeiro
Jan 18, 2018·Pharmacoepidemiology and Drug Safety·Elizabeth A SuarezMichele Jonsson Funk

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.